XBiotech Inc was incorporated in Canada on March 22, 2005. The Company is a clinical-stage biopharmaceutical company engaged in discovering and developing biological therapies including True Human monoclonal antibodies for treating diseases. The Company is also developing MABp1 also known as Xilonix, CA-18C3, CV-18C3, RA-18C3, and T2-18C3 a therapeutic antibody that neutralizes interleukin-1 alpha; IL-1a is a pro-inflammatory protein produced by leukocytes and other cells. The Company completed a Phase I/II clinical trial for MABp1 as a treatment for cancer at MD Anderson Cancer Center. The Company also began using its True Human antibody technology to begin developing a therapy for Ebola virus infection. The Company faces competition from Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceuticals, Daiichi Sanko, Novartis, Roche/Genentech, Janssen, and Xoma/Servier. The Company's business including development, manufacture, distribution, marketing and advertising of drug products are subject to regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar agencies in other countries.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.